Compass Pathways has turned the most watched single-asset psychedelic program in psychiatry into a regulatory countdown. The second-quarter print, delivered on August 5, 2026, carried no new efficacy numbers, and that is the point. Both Phase 3 trials in treatment-resistant depression, or TRD, have already met their primary endpoints, the rolling New Drug Application submission is under way with initial FDA review in progress, and the final filing is targeted for the fourth quarter, with a commercial launch in the first half of 2027 if approval follows. The investment debate has migrated from whether COMP360 works to whether the machinery of approval, rescheduling, and launch executes on schedule, and whether the equity priced at roughly 1.84 billion of market capital has already absorbed that expectation.
The balance sheet underwrites the wait. Cash stood at 433.3 million at the June 30 balance sheet date, a roughly threefold increase from a year earlier. The run-rate of operating spend is modest relative to that war chest. Management frames the runway as extending into 2028, which gives the company room to absorb a slip without a new raise. The reported net loss of 162.6 million for the first half is almost entirely an accounting mirage, a non-cash charge for the fair value of warrant liabilities that rises with the stock price and buried the operating picture. The economically real number is the operating spend of 95.3 million for the half, with research and development declining year over year as pivotal trial enrollment wound down.
The falsifiable clock is short. The COMP006 26-week durability readout lands in early third quarter 2026, and the DEA rescheduling process sits directly on the launch path. If the durability data holds, the filing proceeds without major FDA friction, and rescheduling clears before the first half of 2027, the market is getting the timeline right. If any of those three slips, the gap between a launch story and a financing story widens quickly.